Introduction
New daily persistent headache (NDPH) is one
of the important headache entities under the category of chronic daily
headache. This is the group of primary headache disorders that also
includes chronic migraine, chronic tension-type headache, and hemicrania
continua. Only recently has NDPH been recognized as a distinct entity by
headache specialists.
Key Symptoms
New daily persistent headache is unique in that the headache is daily from
onset, typically in a patient with no prior history. It can continue for years
without any sign of alleviation despite aggressive treatment. The headache will
start one day and in many instances continue as daily and unremitting pain.
There may be two subtypes of
NDPH, a self-limited form which typically goes away within several months
without any treatment, and a refractory form, which is resistant to aggressive
treatment schemes.
A characteristic and unique
feature of NDPH is that most patients are able to pinpoint the exact date when
their headaches started. Headache onset may occur in relationship to an
infection or flu-like illness (e.g.,
mononucleosis), surgery (e.g., hysterectomy), or a stressful life event. NDPH is 2.5 times more likely to occur in
women than men. Average pain intensity is moderate in most people, though some
individuals experience severe pain all of the time.
In order to meet the diagnostic criteria for NDPH, daily pain must be
present for more than two months with untreated headache duration greater than
four hours a day. Headache location is typically bilateral, and pain can occur
anywhere in the head. Pain is usually throbbing or pressing in quality, with
associated symptoms such as nausea, light sensitivity, sound sensitivity, or lightheadedness
occurring in more than half of individuals. Routine physical activity, such as
walking upstairs, may aggravate pain.
Diagnosis
In order to arrive at the diagnosis of NDPH, it is necessary to rule out
other conditions which can mimic this disorder. The two disorders that are
closely similar in presentation include spontaneous cerebrospinal fluid leak
and cerebral venous thrombosis. Special testing is required to assess for these
conditions.
Treatment
NDPH can continue for years and even decades after onset and be extremely
disabling to the individual. Primary NDPH is considered one of the most
difficult headaches to treat. Some NDPH patients do not improve despite
aggressive treatment. However, in the first ever published study, Dr. Rozen of
MHNI, a recognized authority in NDPH, has shown that five cases of NDPH were
successfully treated with varying dosages of gabapentin or topiramate--two
drugs in the neuromodulator group of treatments. We are currently looking at
other possible correlations and physiological abnormalities that may account
for NDPH, thus leading to new and effective therapies.